ORCA Research Selected as Scientific Highlight at ESMO IO 2024
Amsterdam, The Netherlands – December 2024
Prof. Dr. Tanja de Gruijl to Present Clinical Data on ORCA-010 at ESMO Immuno-Oncology Congress 2024
Amsterdam, The Netherlands – November 2024
ORCA Therapeutics to Present Clinical Data on ORCA-010 at International Oncolytic Virus Conference
Amsterdam, The Netherlands – October 2024
ORCA Therapeutics Secures €2 Million in Financing to Advance Oncolytic Immunotherapy Development
Amsterdam, The Netherlands – 23 September 2024
ORCA Therapeutics Achieves Major Regulatory Milestone for Oncolytic Virus Therapy in the Netherlands
Amsterdam, The Netherlands – August 2024
ORCA Therapeutics to Present at the European Association for Cancer Research Congress
Amsterdam, The Netherlands – June 2024
ORCA Therapeutics Welcomes Renowned Oncologist, Prof. Bob Pinedo, MD, PhD, to its Scientific Advisory Board
Amsterdam, The Netherlands – May 2024
ORCA-010 Clinical Study in Prostate Cancer Selected for a Late Breaking Abstract Presentation at the ASGCT conference
Amsterdam, The Netherlands – April 2024
ORCA Therapeutics Chosen for Spotlight Presentation at EACR-AACR-IACR 2024 Conference
Amsterdam, The Netherlands – February 2024
ORCA Therapeutics BV appoints Dr. Wenliang Dong as new CEO
Amsterdam, The Netherlands, November 30, 2023
ORCA Therapeutics BV Announces Completion of Patient Enrollment for Phase II Prostate Cancer Clinical Trial
October 31, 2023
Prof. Victor van Beusechem Presents New Clinical Study Data at ESGCT Congress in Brussels
October 2023
ORCA Therapeutics invited to present on CMC and clinical development of ORCA-010 at the Gene and Cell Therapies: CMC, CGT & Vector Manufacturing + Aseptic Processing Summit
‘s-Hertogenbosch, 17 November 2021.
ORCA Therapeutics to present FIH Clinical Data with enhanced oncolytic immunotherapeutic ORCA-010 at the Society for Immunotherapy of Cancer
‘s-Hertogenbosch, 8 November 2021.
2021.11.08 ORCA Therapeutics to present FIH Clinical Data with enhanced oncolytic immunotherapeutic ORCA at SITCDownload
ORCA Therapeutics to present FIH Clinical Data with enhanced oncolytic immunotherapeutic ORCA-010 at the International Oncolytic Virus Conference
‘s-Hertogenbosch, 4 November 2021.
2021.11.04 ORCA Therapeutics to present FIH Clinical Data with enhanced oncolytic immunotherapeutic ORCA at IOVCDownload
ORCA Therapeutics B.V. to Start Repeat-Dosing in Phase 1/2a Study of ORCA-010 in Treatment-Naïve Prostate Cancer Patients.
‘s-Hertogenbosch, 7 September 2021.
ORCA Therapeutics B.V. to Start Highest Scheduled Dose in Phase 1/2a Study of ORCA-010 in Treatment-Naïve Prostate Cancer Patients. Consistent Efficacy Data from First Cohort and Start New Indication. Additional funding secured.
‘s-Hertogenbosch, 5 March 2021.
Orca Therapeutics Announces Positive DSMB Review in Phase 1/2a Study of ORCA-010 in Treatment-Naïve Prostate Cancer Patients.
‘s-Hertogenbosch, 15 October 2020.
ORCA-010 SHOWS IMPRESSIVE FIRST-LINE PROSTATE CANCER DATA.
‘s-Hertogenbosch, 16 Juli 2020.
ORCA Therapeutics BV Announces Treatment of First Patient in a Phase I/IIa Study with ORCA-010 in Treatment-Naïve Patients with Localized Prostate Cancer.
‘s-Hertogenbosch, 23 December 2019.
ORCA Therapeutics receives approval from Spanish Interministerial Council of Genetically Modified Organisms to use ORCA-010 in a Phase I/IIa study in treatment-naïve prostate cancer patients.
‘s-Hertogenbosch, 4 December 2019.
ORCA Therapeutics receives approval from Health Canada to initiate a Phase I/IIa study with its oncolytic adenovirus ORCA-010 in treatment-naïve prostate cancer patients.
‘s-Hertogenbosch, 1 July 2019.
June 3-6, 2019
14, 2017
VIRION Consortium
The VIRION consortium held their 2nd year meeting in Schiphol on the 13 and 14 of September. ORCA met with the consortium partners and associated partners to discuss the progress made in the program. The overall program was presented and discussed with the H2020 REA representatives.
The progress of the consortium projects, ESR development program and collaboration was evaluated positively by the partners and REA representatives.
June 6, 2017
ORCA Therapeutics is attending the ASCO conference (June 2-6) in Chicago. Get in touch and come see us!
February 13, 2017
ORCA Therapeutics successfully completes preclinical studies on lead cancer drug candidate ORCA-010
READ MORE
September 25, 2016
VIRION Consortium first annual meeting held in Amsterdam
READ MORE
September 2016
Interview with ORCA’s CSO Victor van Beusechem in LabVision (Dutch)
READ MORE
May 25, 2016
On May 27th ORCA’s CSO Victor van Beusechem will give his inaugural lecture entitled: “El Dorado beyond the horizon”
READ MORE
May 4, 2016
ORCA Therapeutics receives Horizon 2020 grant for developing innovative virotherapy for treatment of melanoma
READ MORE
April 1, 2016
ORCA Therapeutics raises €1.5 million for funding nonclinical evaluation and GMP production of their lead product ORCA-010
READ MORE
Follow ORCA Therapeutics
